CoronaryAtlas logo
CoronaryAtlas
Inosine
Pathway / Myocardial injury (shared endpoint)

Inosine

metabolite

Nucleoside byproduct of ATP degradation during myocardial ischemia, signaling rapid cardiomyocyte energy stress.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencehigh
RationaleEarly acute cardiac ischemia marker; metabolic adaptation during hypoxia.
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
43
C — confounder / Type-II
92
A — assay feasibility
42
E — evidence strength
34
T1DI (composite)
4
Specificity differential (R−C)-49.3
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research

Literature evidence(3)